Two new options for NPM1 ‐mutated relapsed, refractory acute myeloid leukemia

Cancer 2026

View at publisher
Authors: Leah Lawrence
DOI: 10.1002/cncr.70275
Cited by: 0
References: 1

Abstract

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, the FDA recently approved two menin inhibitors for the treatment of relapsed or refractory acute myeloid leukemia with NPM1 mutations: revumenib and ziftomenib. In addition, the FDA also approved the subcutaneous injection of anti‐CD38 monoclonal antibody daratumumab and hyaluronidase‐fihj for patients with high‐risk smoldering multiple myeloma, and oral TKI sevabertinib is approved for advanced HER2 ‐mutant NSCLC.

Fields of Study & Subjects

Acute Myeloid Leukemia Research Retinoids in leukemia and cellular processes Chronic Myeloid Leukemia Treatments

Publication details

Journal / source
Cancer
Volume
132
Issue
5
Pages
e70275–e70275
Publication date
1 March 2026
Language
EN